Coherus Oncology (CHRS) Assets Average (2014 - 2026)

Coherus Oncology has disclosed Assets Average across 13 years of filings, most recently posting $228.6 million for Q2 2026.

• In Q2 2026, Assets Average fell 43.59% year-over-year to $228.6 million; the TTM figure through Jun 2026 stood at $228.6 million (down 43.59% YoY), while the FY2025 annual figure was $353.4 million, down 34.44% from the prior year.
• Assets Average came in at $228.6 million for Q2 2026 at Coherus Oncology, down from $262.2 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $719.2 million in Q2 2024 to a low of $228.6 million in Q2 2026.
• Average Assets Average over 5 years is $496.4 million, with a median of $496.9 million recorded in 2022.
• Year-over-year, Assets Average jumped 64.95% in 2024 and sank 43.65% in 2025.
• Over 5 years, Assets Average stood at $515.9 million in 2022, then gained by 17.6% to $606.7 million in 2023, then decreased by 21.42% to $476.8 million in 2024, then fell by 18.74% to $387.4 million in 2025, then sank by 41.0% to $228.6 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $228.6 million in Q2 2026, $262.2 million in Q1 2026, and $387.4 million in Q4 2025.